Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Public ClinicalTrials.gov record NCT03314974. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Myeloablative Allogeneic Hematopoietic Cell Transplantation Using a Related or Unrelated Donor for the Treatment of Hematological Diseases
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further radiation). followed by a post-transplant graft-versus-host disease (GVHD) prophylaxis regimen of post-transplant cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate mofetil (MMF).
Study identification
- NCT ID
- NCT03314974
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 300 participants
Conditions and interventions
Conditions
- Acute Leukemia
- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Lymphoma
- Chronic Myelogenous Leukemia
- Plasma Cell Leukemia
- Myeloproliferative Neoplasms
- Myelofibrosis
- Myelodysplasia
- Refractory Anemia
- High Risk Anemia
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Marginal Zone B-Cell Lymphoma
- Follicular Lymphoma
- Lymphoplasmacytic Lymphoma
- Mantle-Cell Lymphoma
- Prolymphocytic Leukemia
- Diffuse Large Cell Non Hodgkins Lymphoma
- Lymphoblastic Lymphoma
- Burkitt Lymphoma
- High Grade Non-Hodgkin's Lymphoma, Adult
- Multiple Myeloma
- Juvenile Myelomonocytic Leukemia
- Biphenotypic/Undifferentiated/Prolymphocytic Leukemias
- MRD Positive Leukemia
- Natural Killer Cell Malignancies
- Acquired Bone Marrow Failure Syndromes
Eligibility (public fields only)
- Age range
- Up to 60 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 29, 2018
- Primary completion
- Jun 9, 2027
- Completion
- Jun 9, 2028
- Last update posted
- Jun 24, 2026
2018 – 2028
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Masonic Cancer Center at University of Minnesota | Minneapolis | Minnesota | 55337 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03314974, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 24, 2026 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03314974 live on ClinicalTrials.gov.